The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
HER2DX genomic test in HER2-positive breast cancer treated with 15 weeks of neoadjuvant paclitaxel, trastuzumab, and pertuzumab (THP): Final analysis from the BiOnHER clinical trial.
 
Bartomeu Fullana Grimalt
Speakers' Bureau - Eisai; MSD
Travel, Accommodations, Expenses - AstraZeneca; Novartis
 
Fara Brasó-Maristany
No Relationships to Disclose
 
Anna Petit
No Relationships to Disclose
 
Ortega Raúl
No Relationships to Disclose
 
Nadia Gómez
No Relationships to Disclose
 
María Vicente
No Relationships to Disclose
 
Catalina Falo
No Relationships to Disclose
 
Silvia Vazquez
No Relationships to Disclose
 
Agostina Stradella
Consulting or Advisory Role - AstraZeneca; AstraZeneca; AstraZeneca; Gilead Sciences; Novartis; Seagan
Speakers' Bureau - Novartis; Pfizer
Travel, Accommodations, Expenses - Gilead Sciences; Novartis; Novartis; Novartis; Novartis
 
Rafael Villanueva-Vázquez
Consulting or Advisory Role - AstraZeneca; Seagen
Travel, Accommodations, Expenses - AstraZeneca Spain; Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis
 
María Jesús Pla
No Relationships to Disclose
 
David Cordero
No Relationships to Disclose
 
Teresa Soler Monso
No Relationships to Disclose
 
Sandra Cobo
No Relationships to Disclose
 
Laia Pare
Patents, Royalties, Other Intellectual Property - IN VITRO METHOD FOR PREDICTING LONGEVITY IN PATIENTS SUFFERING FROM BREAST CANCER EP 23 383 369.8; IN VITRO METHOD FOR THE PROGNOSIS OF PATIENTS SUFFERING FROM HER2-POSITIVE BREAST CANCER PCT/EP2021/070788; IN VITRO METHOD FOR THE PROGNOSIS OF PATIENTS SUFFERING FROM TRIPLE-NEGATIVE BREAST CANCER EP 23 382 703.9 PCT/EP2024/068197
 
Patricia Galván
No Relationships to Disclose
 
Charles Perou
No Relationships to Disclose
 
Patricia Villagrasa
No Relationships to Disclose
 
Aleix Prat
Employment - Reveal Genomics
Leadership - Reveal Genomics
Stock and Other Ownership Interests - Reveal Genomics
Honoraria - AstraZeneca; Daiichi Sankyo; Novartis; Pfizer; Roche
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Novartis; Oncolytics; Pfizer; Roche
Research Funding - AstraZeneca; Daiichi Sankyo; Novartis (Inst); Roche (Inst)
Patents, Royalties, Other Intellectual Property - HER2DX filing; METHODS FOR BREAST CANCER TREATMENT AND PREDICTION OF THERAPEUTIC RESPONSE (US 63/023785); PCT/EP2016/080056: HER2 AS A PREDICTOR OF RESPONSE TO DUAL HER2 BLOCKADE IN THE ABSENCE OF CYTOTOXIC THERAPY; TNBC-DX
Travel, Accommodations, Expenses - Daiichi Sankyo
Other Relationship - Oncolytics; Peptomyc
 
Sonia Pernas
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Lilly; Novartis; Pfizer; Seagen
Speakers' Bureau - Daiichi Sankyo/Astra Zeneca; Gilead Sciences; Lilly; Novartis; Pfizer; Roche
Research Funding - Roche (Inst)
Travel, Accommodations, Expenses - AstraZeneca; Gilead Sciences; Novartis; Pfizer; Roche
(OPTIONAL) Uncompensated Relationships - SOLTI